All In Biotech

Drug Trial Radar · NCT00175019

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout

Last checked: Nov 20, 2026Latest source record: Jul 27, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,086 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,086

Actual

Start

Jul 2003

Primary completion

Feb 2007

Study completion Feb 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.

Conditions

  • Gout

Interventions

  • FebuxostatDrug

    Febuxostat 80 mg, tablets, orally, once daily.

  • FebuxostatDrug

    Febuxostat 120 mg, tablets, orally, once daily.

  • AllopurinolDrug

    Allopurinol 100 mg or 300 mg, tablets, orally, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.Time frame: Month 1
  2. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.Time frame: Month 12
  3. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.Time frame: Month 24
  4. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.Time frame: Month 36
  5. Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.Time frame: Last Visit on treatment (up to 40 months).

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.